ABBV vs REGN
AbbVie (ABBV) and Regeneron Pharmaceuticals (REGN) compared side by side. AbbVie (ABBV) is larger, with a market cap of $504.8B versus $82.9B for Regeneron Pharmaceuticals, about 6.1 times the size. On trailing earnings, REGN is cheaper at 19.9x versus 80.7x for ABBV.
Head to head
| Metric | ABBV | REGN |
|---|---|---|
| Market cap | $504.8B | $82.9B |
| P/E (TTM) | 80.7x | 19.9x |
| Forward P/E | 17.6x | 12.8x |
| Revenue (TTM) | $64.4B | $15.5B |
| Revenue growth | 10.2% | 16.7% |
| Gross margin | 72.8% | 44.5% |
| Operating margin | 40.0% | 33.1% |
| Free cash flow | $18.2B | $3.6B |
| Dividend yield | 2.42% | 0.47% |
| 1-year return | +28.9% | +40.6% |
| 5-year return (annual) | +25.6% | +7.3% |
| Max drawdown | -45% | -92% |
| FI Handbook grade | B | B+ |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
ABBV vs REGN FAQ
Which is bigger, ABBV or REGN?
AbbVie (ABBV) is larger, with a market cap of $504.8B versus $82.9B for Regeneron Pharmaceuticals, about 6.1 times the size.
Is ABBV or REGN cheaper?
On trailing earnings, REGN is cheaper at 19.9x versus 80.7x for ABBV. A lower P/E can reflect slower expected growth, so compare growth and margins too.
Which stock performed better over the past year, ABBV or REGN?
REGN returned +40.6% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026.
Which pays a higher dividend, ABBV or REGN?
ABBV yields 2.42% versus 0.47% for REGN.
Full pages: AbbVie · Regeneron Pharmaceuticals